Jazz Pharmaceuticals gets US FDA approval of Xywav for cataplexy associated with narcolepsy
Jazz Pharmaceuticals plc announced that the U.S. Food and Drug Administration (FDA) approved Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution on July 21, 2020…
Read More...
Read More...
